HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) web only table Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Stearns, V. Search for Related Content PubMed PubMed Citation Articles by Stearns, V. Topic Collections Relevant Article

Raloxifene and tamoxifen had similar efficacy for preventing invasive breast cancer in women at increased risk

Clinical impact ratings GP/FP/Primary care Oncology Endocrine

Key Words: breast neoplasms • raloxifene • selective oestrogen receptor modulators • tamoxifen

The first 150 words of the full text of this article appear below.

METHODS
Design: randomised controlled trial.

Allocation: concealed.^*

Blinding: blinded (clinicians, participants, and outcome assessors).^*

Follow up period: mean 3.9 years.

Setting: nearly 200 clinical centres in North America.

Participants: 19 747 postmenopausal women 35 years of age (mean age 59 y) whose 5 year predicted risk of breast cancer was 1.66% (mean 4.03%) based on the Gail model. Exclusion criteria included recent hormone therapy use; stroke or venous thromboembolism (VTE) history; cancer in the previous 5 years; and uncontrolled atrial fibrillation, diabetes, or hypertension.

Intervention: raloxifene, 60 mg/day (n = 9875), or tamoxifen, 20 mg/day (n = 9872), for a maximum 5 years.

Outcomes: invasive breast cancer, non-invasive breast cancer, uterine cancer, uterine hyperplasia, ischaemic heart disease, stroke, VTE, osteoporotic fractures, cataracts, and death.

Patient follow up: 99% (intention to treat analysis).

MAIN RESULTS
The table shows the results for significant differences. Groups did not differ for invasive or non-invasive breast cancer, ischaemic . . . [Full text of this article]

Vered Stearns, MD

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,
Baltimore, Maryland, USA

Relevant Article

Glossary
Evid. Based Med. 2006 11: 191. (in Glossary) [Extract] [Full Text] [PDF]